Literature DB >> 12897156

Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression.

H Karimi Kinyamu1, Trevor K Archer.   

Abstract

Glucocorticoids and estrogens regulate a number of vital physiological processes. We developed a model breast cancer cell line, MCF-7 M, to examine potential mechanisms by which the ligand-bound estrogen receptor (ER) regulates glucocorticoid receptor (GR)-mediated transcription. MCF-7 cells, which endogenously express ERalpha, were stably transfected with mouse mammary tumor virus promoter-luciferase (MMTV-LUC) reporter and GR expression constructs. Our results demonstrate that treatment with estrogen agonists (17beta-estradiol [E2], diethylstilbestrol, genistein), but not antagonists (tamoxifen or raloxifene), for 48 h inhibits GR-mediated MMTV-LUC transcription and chromatin remodeling. Furthermore, estrogen agonists inhibit glucocorticoid induction of p21 mRNA and protein levels, suggesting that the repressive effect applies to other GR-regulated genes and proteins in MCF-7 cells. Importantly, GR transcriptional activity is compromised because treatment with estrogen agonists down regulates GR protein levels. The protein synthesis inhibitor cycloheximide and the proteasome inhibitor MG132 block E2-mediated decrease in GR protein levels, suggesting that estrogen agonists down regulate the GR via the proteasomal degradation pathway. In support of this, we demonstrate that E2-mediated GR degradation is coupled to an increase in p53 and its key regulator protein Mdm2 (murine double minute 2), an E3 ubiquitin ligase shown to target the GR for degradation. Using the chromatin immunoprecipitation assay, we demonstrate an E2-dependent recruitment of ERalpha to the Mdm2 promoter, suggesting a role of ER in the regulation of Mdm2 protein expression and hence the enhanced GR degradation in the presence of estrogen agonists. Our study shows that cross talk between the GR and ER involves multiple signaling pathways, indicative of the mechanistic diversity within steroid receptor-regulated transcription.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12897156      PMCID: PMC166332          DOI: 10.1128/MCB.23.16.5867-5881.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  79 in total

1.  Cloning of a novel receptor expressed in rat prostate and ovary.

Authors:  G G Kuiper; E Enmark; M Pelto-Huikko; S Nilsson; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

2.  Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells.

Authors:  L Whitesell; P Cook
Journal:  Mol Endocrinol       Date:  1996-06

3.  Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids.

Authors:  A D Wallace; J A Cidlowski
Journal:  J Biol Chem       Date:  2001-09-12       Impact factor: 5.157

4.  Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53.

Authors:  D P Xirodimas; C W Stephen; D P Lane
Journal:  Exp Cell Res       Date:  2001-10-15       Impact factor: 3.905

5.  Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer.

Authors:  Masao Hori; Jiro Shimazaki; Satoshi Inagawa; Masayuki Itabashi; Mitsuo Hori
Journal:  Breast Cancer Res Treat       Date:  2002-01       Impact factor: 4.872

6.  Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate.

Authors:  Wayne A Fritz; Jun Wang; Isam Eldin Eltoum; Coral A Lamartiniere
Journal:  Mol Cell Endocrinol       Date:  2002-01-15       Impact factor: 4.102

7.  Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin.

Authors:  S K Shenoy; P H McDonald; T A Kohout; R J Lefkowitz
Journal:  Science       Date:  2001-10-04       Impact factor: 47.728

8.  17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells.

Authors:  L Altucci; R Addeo; L Cicatiello; S Dauvois; M G Parker; M Truss; M Beato; V Sica; F Bresciani; A Weisz
Journal:  Oncogene       Date:  1996-06-06       Impact factor: 9.867

9.  Visualization of glucocorticoid receptor translocation and intranuclear organization in living cells with a green fluorescent protein chimera.

Authors:  H Htun; J Barsony; I Renyi; D L Gould; G L Hager
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

Review 10.  The nuclear receptor superfamily: the second decade.

Authors:  D J Mangelsdorf; C Thummel; M Beato; P Herrlich; G Schütz; K Umesono; B Blumberg; P Kastner; M Mark; P Chambon; R M Evans
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

View more
  62 in total

Review 1.  Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses.

Authors:  Laura N Vandenberg; Theo Colborn; Tyrone B Hayes; Jerrold J Heindel; David R Jacobs; Duk-Hee Lee; Toshi Shioda; Ana M Soto; Frederick S vom Saal; Wade V Welshons; R Thomas Zoeller; John Peterson Myers
Journal:  Endocr Rev       Date:  2012-03-14       Impact factor: 19.871

2.  Lysine 419 targets human glucocorticoid receptor for proteasomal degradation.

Authors:  Andrew D Wallace; Yan Cao; Sindhu Chandramouleeswaran; John A Cidlowski
Journal:  Steroids       Date:  2010-07-07       Impact factor: 2.668

3.  TRIM25 has a dual function in the p53/Mdm2 circuit.

Authors:  P Zhang; S Elabd; S Hammer; V Solozobova; H Yan; F Bartel; S Inoue; T Henrich; J Wittbrodt; F Loosli; G Davidson; C Blattner
Journal:  Oncogene       Date:  2015-03-02       Impact factor: 9.867

Review 4.  Mechanisms and significance of nuclear receptor auto- and cross-regulation.

Authors:  Pia Bagamasbad; Robert J Denver
Journal:  Gen Comp Endocrinol       Date:  2010-03-23       Impact factor: 2.822

5.  Regulation of p53 and MDM2 activity by MTBP.

Authors:  Mark Brady; Nikolina Vlatkovic; Mark T Boyd
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

6.  Chromatin-dependent cooperativity between site-specific transcription factors in vivo.

Authors:  Pratibha B Hebbar; Trevor K Archer
Journal:  J Biol Chem       Date:  2006-12-23       Impact factor: 5.157

7.  Robust and comprehensive analysis of 20 osteoporosis candidate genes by very high-density single-nucleotide polymorphism screen among 405 white nuclear families identified significant association and gene-gene interaction.

Authors:  Dong-Hai Xiong; Hui Shen; Lan-Juan Zhao; Peng Xiao; Tie-Lin Yang; Yan Guo; Wei Wang; Yan-Fang Guo; Yong-Jun Liu; Robert R Recker; Hong-Wen Deng
Journal:  J Bone Miner Res       Date:  2006-11       Impact factor: 6.741

8.  Glucocorticoid receptor expression in breast cancer associates with older patient age.

Authors:  Larissa Belova; Bertha Delgado; Masha Kocherginsky; Amal Melhem; Olufunmilayo I Olopade; Suzanne D Conzen
Journal:  Breast Cancer Res Treat       Date:  2008-07-31       Impact factor: 4.872

9.  Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.

Authors:  H Karimi Kinyamu; Jennifer B Collins; Sherry F Grissom; Pratibha B Hebbar; Trevor K Archer
Journal:  Mol Carcinog       Date:  2008-11       Impact factor: 4.784

Review 10.  The Role of MDM2 Amplification and Overexpression in Tumorigenesis.

Authors:  Jonathan D Oliner; Anne Y Saiki; Sean Caenepeel
Journal:  Cold Spring Harb Perspect Med       Date:  2016-06-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.